BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Day In Review: GFS Chemicals, Inc. Panel Approves Diabetes Drug Exubera


10/19/2005 5:09:15 PM

September 8, 2005 An FDA panel recommended the inhaled form of insulin, Exubera, from Pfizer, Sanofi-Aventis and Nektar; Barr Labs will pay $142 million to acquire a contraceptive from Organon and Savient Pharma; Caliper Life Sciences will pay $22 million to buy NovaScreen Biosciences, which offers research services; Indevus began a Phase III trial of its overactive bladder drug; and animal rights activists prevented Life Sciences Research from listing on the NYSE. Biotech executed a small retreat on Thursday, with the Centient Biotech 200 losing almost 16 points to close at 3890.31, a drop of .41%. More details...

Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES